Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 13/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16883679 | 0.84 | PGR (0.46) | PGRDAOKDM4EALDH1A1 | |
| SCHEMBL20079376 | 0.83 | PGR (0.43) | PGRARKDM4EALDH1A1 | |
| SCHEMBL20079380 | 0.80 | DAO (0.58) | PGRPOLBMAOBDAOALDH1A1 | |
| SCHEMBL20079382 | 0.80 | PGR (0.55) | PGRPOLBMAOBDAOALK | |
| SCHEMBL20079383 | 0.79 | POLB (0.51) | PGRPOLBMAOBDAOALDH1A1 | |
| SCHEMBL18358723 | 0.75 | PSMB8 (0.44) | PGRARALDH1A1 | |
| SCHEMBL25433823 | 0.74 | PGR (0.43) | PGRPOLBMAOB | |
| SCHEMBL20656270 | 0.74 | PGR (0.69) | PGRPOLBMAOBDAOAR | |
| SCHEMBL20079386 | 0.73 | PGR (0.54) | PGRPOLBMAOBDAO | |
| SCHEMBL25352403 | 0.71 | PGR (0.41) | PGRPOLBMAOBDAOKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200179357-A1 | TRPA1 ANTAGONISTS FOR TREATMENT OF DRY EYE, OCULAR PAIN AND INFLAMMATION | ALGOMEDIX INC (US) | 2020-06-11 | — | — | US | disclosed |
| US-10428049-B2 | TRPA1 modulators | ALGOMEDIX, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190016701-A1 | TRPA1 MODULATORS | ALGOMEDIX, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-9951046-B2 | TRPA1 modulators | ALGOMEDIX, INC. (US) | 2018-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428049-B2 | TRPA1 modulators | TRPA1, TRPV1, TRPV2 | PGR 3776/4885POLB 4513/4885MAOB 2508/4885 |
| US-20190016701-A1 | TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | PGR 3776/4885POLB 4513/4885MAOB 2508/4885 |
| US-20200179357-A1 | TRPA1 ANTAGONISTS FOR TREATMENT OF DRY EYE, OCULAR PAIN AND INFLAMMATION | TRPA1, TRPV1, TRPV2 | PGR 4156/4885POLB 4439/4885MAOB 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.